| |
|
|
MADISON, Wisconsin - July 31, 2000--SLIL Biomedical Corp. announced the addition of George Wilding, M.D. to its Scientific Advisory Board. Dr. Wilding, a leading expert in prostate cancer, is Professor and Head of the Medical Oncology Section of the Department of Medicine at the University of Wisconsin-Madison-(UW). In addition, he serves as the Associate Director for Clinical Programs, Director of the Experimental Therapeutics Program and the Co-Director of the Genitourinary Cancer Program at the UW Comprehensive Cancer Center. Dr. Wilding also serves as Chair of the Genitourinary Cancer Committee for the Eastern Cooperative Oncology Group. Dr. Wilding is on the advisory board of a number of biotechnology and pharmaceutical companies. Dr. Wilding earned his M.D. from the University of Massachusetts Medical School, a M.S. in Pharmacology from Pennsylvania State University, and a B.S. in both Chemical Engineering and Biology from Tufts University. SLIL Biomedical Corp. is an early-stage drug discovery company focused on developing new treatments to fight cancer. SLIL is a leader in the development of novel polyamine analogs as anti-cancer agents and has proprietary Tumor Targeting and Delivery technologies (TTD™). The Company currently has a pipeline of 16 lead compounds from these technologies. SLIL also has an exclusive license to the Sequential Pathogenesis Model technology from the University of California-San Francisco that has far reaching potential diagnostic and prognostic applications for cancer and other diseases. SLIL has its headquarters and drug discovery activities in Madison, Wisconsin and additional research facilities, dedicated to the Sequential Pathogenesis Model technology, in Menlo Park, California. SOURCE: SLIL Biomedical Corp. Contact: Marla K. Johnson SLIL Biomedical Corp.
|